current state develop cystic fibrosi compet tripl combo
data second half
report review current state develop discuss outlook
recent month vertex share strengthen due combin misstep
mix data readout competitor galapagos/abbvi proteostasi
excel phase ii data tripl combin ultra-quick
timelin requir execut phase studi top-lin data readout expect
cystic fibrosi cf treatment landscap highlight compani coverag
vertex outperform well product candid key
catalyst compani includ galapago glpg partner
proteostasi pti
earli june galapagos/abbvi report disappoint top-lin data
pelican trial phase ii studi assess corrector
combin orkambi lumacaftor ivacaftor result demonstr mean
absolut improv percent predict forc expiratori volum one second
four week meanwhil also chose proceed
plan second tripl combin studi current review collabor
compani potenti delay timelin first tripl combin
studi falcon on-going data expect third quarter also june
proteostasi present mix result phase studi third-gener corrector
also add-on orkambi three dose mg mg
mg orkambi best result came mg cohort show
mean absolut improv comparison vertex demonstr
improv around ad third-gener corrector
doubl combo symdeko tezacaftor ivacaftor top-lin data phase studi
vertex tripl combo expect earli note primari efficaci endpoint
evalu week safeti endpoint weeksthi ultra-short studi design
greatli acceler time market vertex tripl combo
return equiti ttm
biopharmaceut compani focus develop commerci therapi
cystic fibrosi compani lead asset kalydeco kalydeco lumacaftor combo registr next-
gener combin clinic develop
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
despit unimpress orkambi add-on data date discuss detail herein tripl combo data
galapago third quarter proteostasi fourth quarter first indic strength
true testament competitor view time increas fair valu estim
vertex share increas vertex initi market share equilibrium share cf market
respect base acknowledg timelin delay competitor
develop continu assign probabl success vertex tripl combo excit scientif
medic breakthrough led vertex pois solv cf problem market perform thesi
vertex share sole base view competit market dynam compet tripl combo data
demonstr increas homozyg het/min patient expect vertex share come
current level competitor fail meet mark see sizabl upsid vertex share lead
earli phase readout monopol cf market forese futur
caveat orkambi add-on studi lead us wait tripl combo data galapago proteostasi
draw definit conclus competit regimen observ subset patient
treat orkambi respond acut drop dose wherea symdeko produc stabl
consist respons hypothes interact orkambi compon kalydeco ivacaftor
lumacaftor could contribut effect galapagoss proteostasiss evalu top
orkambi homozyg patient produc improv respect far less impress
improv seen vertex trial combin investig corrector symdeko
patient popul similarli result mmol/l drop sweat chlorid pti-
achiev mmol/l reduct fall far short vertex symdeko-bas tripl reduc
sweat chlorid mmol/l effect correct sweat chlorid level non-cf state due curiou
characterist orkambi vertex never evalu second-gener corrector top orkambi
believ fair comparison vertex tripl data competitor difficult accur assess stage
galapago corrector pti corrector bind differ site cftr cystic fibrosi
transmembran conduct regul vertex second-gener corrector
competitor corrector optim combin respect compound evidenc vitro
assay drug-drug interact studi reason continu wait tripl combo data galapago
proteostasi first valid testament potenti program tripl achiev least
improv homozyg het/min patient accompani mmol/l drop sweat chlorid
believ view credibl competit vertex
pelican design data summari june compani report top-lin result pelican
trial phase ii studi assess corrector top orkambi homozyg patient show
disappoint efficaci although well-toler safeti profil pelican studi enrol patient
stabl orkambi least week prior begin trial patient random add
placebo continu orkambi treatment anoth four week follow anoth three week
observ studi met primari efficaci endpoint mean chang sweat chlorid concentr
baselin day demonstr decreas mmol/l versu placebo howev mean absolut
improv day statist signific patient experienc mean
chang baselin compar placebo safeti side well-toler low
rate advers event similar placebo death seriou advers event
prematur discontinu due
top-lin data falcon compani phase ii studi evalu first proprietari tripl combin
expect third quarter falcon tripl combo studi evalu potenti corrector
corrector part one studi enrol eight homozyg patient receiv
two week add anoth two week part two enrol anoth cohort homozyg patient
cohort heterozyg patient eight subject receiv regimen use first part
studi higher dose although dose detail disclos manag note dose least one
compon increas part one part two data part one studi anticip third
quarter date vertex demonstr impress tripl combo result data two phase ii
tripl combo studi het/min patient symdeko tezacaftor ivacaftor symdeko set
benchmark demonstr increas reach believ falcon studi would need
close increas least homozyg het/min patient accompani sweat
chlorid declin respiratori function improv competit vertex tripl combo
retreat collabor undisclos reason leav mani question mark
collabor move forward initi second tripl combo studi consist potenti
corrector corrector stall collabor current review
although galapago express intent move program forward even without partner suspect
might concern first potenti use falcon long half-
life one month make less ideal use once-daili regimen might lead safeti liabil howev
decis move forward second tripl combin switch next-gener
potenti came someth surpris us sinc once-daili compound stall decis
could also come disappoint orkambi add-on data corrector pelican note
galapago anoth corrector suppos third tripl combo corrector
corrector caveat add-on studi orkambi discuss
junctur unclear aspect tripl combo profil develop strategi grave concern
whether could resolut differ partnership
orkambi studi design data summari similar unimpress outcom observ pelican
june proteostasi present mix interim result phase studi third-gener corrector pti-
add-on orkambi homozyg patient trial enrol patient stabl orkambi add one
three dose mg mg mg qd on-going orkambi therapi two week best
efficaci mg cohort demonstr mean absolut improv
howev signific improv observ sweat chlorid decreas mmol/l bodi mass index
weight blood glucos level manag believ also import overal clinic benefit chang
addit endpoint strongest mg dose group compani enrol anoth
patient higher dose
proteostasiss phase ii studi add-on symdeko could answer question potenti differ
orkambi symdeko phase ii studi homozyg patient stabl orkambi ad
mg amplifi qd top continu orkambi treatment day led increas
baselin compar placebo mean rel improv treatment effect
achiev day sustain cours trial addit studi ad top
stabl symdeko anticip read earli comparison data two studi might provid
glimps differ orkambi symdeko although corrector pti-
proteostasi initi tripl combin studi cf patient initi data expect fourth
quarter proteostasi put togeth tripl combo amplifi corrector
potenti demonstr restor cftr function wild type activ
homozyg hbe human bronchial epitheli cell level activ similar better
demonstr vertex galapagos/abbvi tripl combo vitro unclear moment whether
vitro data would translat human efficaci linearli therefor phase proof-of-concept data
proprietari tripl combin expect fourth quarter close watch efficaci novel
combo need prove long-term safeti acknowledg vertex tripl combo advantag
well symdeko alreadi approv well toler ad second-gener corrector vx-
bear much less safeti risk put three novel unproven compound togeth case
galapago proteostasi
vertex extend cf franchis lead compani announc strong phase ii result tripl
combin studi evalu next-gener corrector top symdeko compani look reproduc
potenti improv upon magnitud increas observ phase ii studi
homozyg patient top semdeko around het/min patient phase tripl
combin data readout earli tripl combo pois transform care cf
popul set high bar competit come vertex demonstr impress data date
includ increas het/min subgroup accompani substanti sweat chlorid declin
respiratori function improv along seemingli good safeti profil composit vertex two tripl combo
symdeko tezacaftor ivacaftor symdeko tripl combo studi het/min
mutat one allel minim function mutat popul homozyg
phase studi design shorten trial durat expedit timelin approv due safeti
demonstr kalydeco orkambi symdeko approv estim top-lin data
het/min patient studi avail earli serv key catalyst vertex share
continu place probabl commerci two set phase studi ident
design target enrol patient het/min trial patient
homozyg trial studi design support ex-u registr compani strategi
test two differ next-gen corrector-bas combin parallel intend help identifi benefici
regimen patient maxim speed market patient studi random receiv
symdeko placebo symdeko het/min studi primari efficaci endpoint mean
absolut chang lung function baselin week compar placebo safeti evalu
week follow long-term open-label extens homozyg studi patient begin
four-week run symdeko follow anoth four week ad next-gener corrector placebo
roll long-term tripl combo extens primari efficaci endpoint studi mean absolut
chang lung function end run-in period end four-week experiment period tripl
combo patient versu placebo symdeko patient regulatori submiss homozyg patient
safeti evalu throughout cours studi supplement safeti data
regimen correspond trial het/min patient note prior pivot studi orkambi symdeko
efficaci safeti endpoint contrast current phase tripl combin studi het/min
patient cut half greatli acceler timelin approv high unmet need popul
abil supplement homozyg safeti data long-term result larger set het/min
patient help creat stronger data packag patient also shorten time regulatori
submiss second indic data studi expect earli serv key
catalyst vertex share
competit like requir much longer endpoint collect suffici safeti data discuss two
on-going tripl combo studi primari efficaci assess week safeti assess week
much acceler develop timelin compar kalydeco orkambi whose durat
pivot studi six month efficaci one year safeti follow-up competit tripl combo studi
like requir conduct longer studi compar durat kalydeco orkambi build
safeti databas would put vertex ahead tripl combo race
given vertex group alreadi approv cf drug compani commerci organ infrastructur
alreadi establish competit would like face much higher hurdl move forward clinic
commerci possibl retreat collabor galapago may move forward solo without
help establish experienc commerci team given proteostasiss size lack
commerci experi compani may seek partnership move program forward
made chang cf market model exhibit increas equilibrium market share
vertex lower equilibrium market share galapagos/abbvi due increas confid vertex
first-to-market tripl combo may sticki uncertainti surround galapagoss cf program updat
model chang equilibrium market share unit state vertex galapago proteostasi
respect result peak sale vertex increas
billion billion meanwhil peak sale galapagos/abbvi decreas billion
maintain market perform rate increas fair valu estim vertex share
ahead compet tripl combo data releas year-end exhibit npv model valu
compani cf franchis per share togeth net cash per share end deriv fair valu
vertex share note model includ valu program cf gene therapi
upcom catalyst includ initi data part one phase studi symdeko third quarter
updat path forward top-lin data phase studi symdeko
earli nda submiss approv tripl combin second half initi proof-of-concept
data vertex program outsid cystic fibrosi next one two year
risk outperform rate vertex includ stronger competit data cf inabl develop tripl
combo therapi setback relat clinic preclin busi develop activ
dollar thousand drugpeak salesstag ofdevelopmentestim launch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuekalydeco cystic fibrosi gate marketedfebruari combo cystic homozyg market orkambi pre-registr kalydeco/tezacaftor juli combofor cystic phase year-end present valu addit gain loss fair includ cost directli relat program abovesourc compani report william blair compani estimatesexhibit incorporatedsum-of-part fair valuesourc william blair compani estimatesexhibit incorporatedcyst fibrosi market model import disclosur
